Physician profile
Scottie L Smith
NPI 1386048866
$7,938.73
in general payments reported to CMS, 2019-2025
29 companies · $1,288 in 2025
The $1,288 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,457 · 2022: $1,978 · 2023: $1,579 · 2024: $1,637 · 2025: $1,288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,407 · Education: $97.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,407.33 |
| Education | $97.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,338.69 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,183.97 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $679.02 | 2021-2024 | Trulance |
| Janssen Biotech, INC. | $252.15 | 2022-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $239.38 | 2022-2024 | Dupixent |
| Merck Sharp & Dohme LLC | $234.00 | 2021-2024 | Dificid |
| Lilly USA, LLC | $207.22 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $197.77 | 2021-2024 | |
| Qol Medical, LLC | $180.66 | 2021-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $155.46 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $152.84 | 2022-2024 | Ibsrela |
| Daiichi Sankyo INC. | $146.97 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $140.23 | 2021-2024 | Linzess |
| Nestle Healthcare Nutrition INC. | $137.64 | 2021-2023 | |
| Genzyme Corporation | $116.43 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $94.95 | 2024-2025 | Voquezna |
| Pharmacosmos Therapeutics INC. | $76.21 | 2022-2025 | Monoferric |
| Celgene Corporation | $73.38 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $57.68 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $47.86 | 2023-2025 | Vegzelma, Yuflyma |
| Redhill Biopharma INC. | $38.77 | 2021-2022 | |
| Braintree Laboratories, INC. | $38.08 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $34.14 | 2023 | Andexxa |
| Mallinckrodt Hospital Products INC. | $29.81 | 2022 | |
| Amgen INC. | $24.93 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $17.80 | 2021 | |
| Novo Nordisk INC | $16.41 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.31 | 2023 | Cyltezo |
| Ethicon US, LLC | $11.97 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scottie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.